Inhibition of mTORC1 by SU6656, the Selective Src Kinase Inhibitor, Is Not Accompanied by Activation of Akt/PKB Signalling in Melanoma Cells

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11110%2F13%3A10191811" target="_blank" >RIV/00216208:11110/13:10191811 - isvavai.cz</a>

Výsledek na webu

<a href="http://fb.cuni.cz/file/5696/FB2013A0023.pdf" target="_blank" >http://fb.cuni.cz/file/5696/FB2013A0023.pdf</a>

DOI - Digital Object Identifier

—

Jazyk výsledku

angličtina

Název v původním jazyce

Inhibition of mTORC1 by SU6656, the Selective Src Kinase Inhibitor, Is Not Accompanied by Activation of Akt/PKB Signalling in Melanoma Cells

Popis výsledku v původním jazyce

The mammalian target of rapamycin (mTOR) is a Ser/Thr protein kinase conserved in all eukaryotes that plays a key role in cell growth and is a central effector of several pathways regulating essential cell functions. Hyperactivation of the mTOR-dependentsignalling pathway occurs in many human diseases and may be a selective target for their therapy. However, the dual nature of mTOR, existing in two multiprotein complexes mTORC1 and mTORC2 driven by different feedback loops, decreases the therapeutic effects of rapamycin, the specific mTOR inhibitor. In the present study we demonstrate that the mTORC1 signalling pathway is highly activated in human melanoma cells and that up-regulation of this pathway along with the growth and malignity of these cellscould be suppressed by disruption of the Src activity. SU6656, the selective inhibitor of the Src kinase activity, decreased up-regulation of the mTORC1 signalling and moreover, unlike rapamycin, it did not induce the activation of Akt/PK

Název v anglickém jazyce

Inhibition of mTORC1 by SU6656, the Selective Src Kinase Inhibitor, Is Not Accompanied by Activation of Akt/PKB Signalling in Melanoma Cells

Popis výsledku anglicky

The mammalian target of rapamycin (mTOR) is a Ser/Thr protein kinase conserved in all eukaryotes that plays a key role in cell growth and is a central effector of several pathways regulating essential cell functions. Hyperactivation of the mTOR-dependentsignalling pathway occurs in many human diseases and may be a selective target for their therapy. However, the dual nature of mTOR, existing in two multiprotein complexes mTORC1 and mTORC2 driven by different feedback loops, decreases the therapeutic effects of rapamycin, the specific mTOR inhibitor. In the present study we demonstrate that the mTORC1 signalling pathway is highly activated in human melanoma cells and that up-regulation of this pathway along with the growth and malignity of these cellscould be suppressed by disruption of the Src activity. SU6656, the selective inhibitor of the Src kinase activity, decreased up-regulation of the mTORC1 signalling and moreover, unlike rapamycin, it did not induce the activation of Akt/PK

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

CE - Biochemie

OECD FORD obor

—

Projekt

<a href="/cs/project/NT11231" target="_blank" >NT11231: Ovlivnění signálních drah mTOR a MAPK inhibicí kinázové aktivity Src - význam pro individualizovanou protinádorovou terapii</a><br>

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Rok uplatnění

2013

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Folia Biologica

ISSN

0015-5500

e-ISSN

—

Svazek periodika

59

Číslo periodika v rámci svazku

4

Stát vydavatele periodika

CZ - Česká republika

Počet stran výsledku

6

Strana od-do

162-167

Kód UT WoS článku

000326215400004

EID výsledku v databázi Scopus

—